Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Introduces Draft Guideline for RA Management

Jason Liebowitz, MD, FACR  |  November 23, 2020

The speakers described how this recommendation is meant to encourage rheumatologists to limit the use of steroids as much as possible given the potential harms associated with this medication class. The members of the guideline committee noted that glucocorticoid use is appropriate to help patients with acutely active RA. However, minimizing steroid use to periods when such treatment is absolutely needed is the ideal path for rheumatologists to follow.

Tapering Recommendations
As part of the panel discussion, the subject of tapering medications arose, and the speakers provided helpful insight into the topic. Often when patients feel better with regard to their RA symptoms, they ask their rheumatologist if and when they can taper their medications to avoid potential side effects, save time and money with respect to treatment, and achieve other potential benefits.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For this draft guideline, a discussion of tapering was recommended only if a patient has achieved target disease control for at least six months. At that point, it would be reasonable for the rheumatologist to discuss tapering medications with the patient, while including a full and informed discourse about the potential for flares. Back-up plans for situations in which disease activity increases should also be addressed.

Dr. England

Implications
Finally, Bryant England, MD, PhD, assistant professor of internal medicine in the Division of Rheumatology, University of Nebraska Medical Center, Omaha, noted the committee has provided a roadmap for how the field of rheumatology can and should seek to answer the pressing research questions of our era.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

By specifically working on the most clinically challenging and relevant issues, researchers can provide the data that will allow recommendations in future guideline documents to be made with strong evidentiary support. This approach will, in turn, help clinicians, who will be able to refer to robust data and recommendations to support what they do in clinical practice.


Jason Liebowitz, MD, completed his fellowship in rheumatology at Johns Hopkins University, Baltimore, where he also earned his medical degree. He is currently in practice with Skylands Medical Group, N.J.

References

  1. Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017 Sep;37(9):1551–1557.
  2. O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013 Jul 25;369(4):307–318.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Related Articles
    MDGRPHaCS / shutterstock.com

    The ACR Releases an Updated Treatment Guideline for Rheumatoid Arthritis

    June 14, 2021

    In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…

    Meet the HEP C Challenge

    December 1, 2008

    Keep a hepatitis C virus infection from hindering RA treatment

    A Guiding Light for RA: Insights into Clinical Decision Making, Drug Safety & More

    August 11, 2022

    The treatment and management of rheumatoid arthritis (RA) is ever evolving. Here Clifton O. Bingham, MD, discusses the application of RA guidelines, the most recent drug safety information and more.

    Shared Decision Making, Good Disease Control Are Key Components of JIA Management

    May 15, 2019

    A group led by Sarah Ringold, MD, MS, assistant professor of rheumatology at Seattle Children’s Hospital, has developed a new guideline intended to provide recommendations for the treatment and monitoring of children with juvenile idiopathic arthritis (JIA) manifesting as non-systemic polyarthritis, sacroiliitis or enthesitis.1,2 Key Updates The new recommendations appear in both Arthritis & Rheumatology…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences